Medigene’s proprietary end-to-end platform enables the development of differentiated, best-in class T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Medigene develops these therapies on its own or in partnership.
- Discovery Stage
- CTA/IND-enabling
- Clinical Studies
Multiple Solid Tumor Types
NY-ESO-1 + PD1-41BB / HLA-A2
CTA / IND 2H 2024
Medigene’s lead candidate targeting NY-ESO-1 combined with our PD1-41BB costimulatory switch receptor.
Undisclosed Targets / Undisclosed HLAs + PD1-41BB
Lead selection 2H 2023
Generation of TCR T cells targeting appropriate antigens with several different HLA types each developed and improved with our optimization technologies and combined with our PD1-41BB costimulatory switch receptor.
PRAME / HLA-A2
Milestones set by BioNtech
Exclusively partnered with BioNtech. Also includes non-exclusive licenses to our optimization technologies
MAGE-A4 / HLA-A2
Milestones set by 2seventy bio
Exclusively partnered with 2seventy bio.
NY-ESO-1 / HLA-A2
Milestones set by Hongsheng Sciences
Exclusively partnered with Hongsheng Sciences.
Multiple Liquid Tumor Types
PRAME / HLA-A2
NY-ESO-1 / HLA-A2
Milestones set by Hongsheng Sciences
Exclusively partnered with Hongsheng Sciences.